First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine … – Markets Insider
|
First in Human Administration of UCART123 in Cellectis' AML Phase I Clinical Trial at Weill Cornell Medicine …
Markets Insider Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), announced today the first administration in the Phase I clinical study in Acute … |
